The application of artificial intelligence (AI) to address challenges in health care is almost universally described as transformative. Acknowledging the rapid pace at which tools incorporating AI have advanced toward clinical practice, prior JAMA editorials1,2 noted the importance of ensuring the…
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and sell an experimental cancer drug, the…
Borrowing a page from cancer’s playbook, scientists learn to evade their own therapies
This cohort study examines if rates of overtreatment of men with prostate cancer with limited life expectancy have persisted in the active surveillance era and…
Tanios S. Bekaii-Saab, MD, discusses the evolution of frontline treatment in advanced pancreatic cancer.
Communications Medicine – Smelik et al. investigate the effectiveness of using multi-omics biomarkers in blood for cancer screening. The results indicate that while these biomarkers…
This JAMA Patient Page describes knee osteoarthritis and its symptoms, diagnosis, and treatments.
Over 2 decades ago, the mineralocorticoid receptor antagonist (MRA), spironolactone was demonstrated to substantially reduce the risk of all-cause mortality along with heart failure (HF)…
This multicenter secondary analysis of the FINEARTS-HF randomized clinical trial examines the treatment effect of finerenone, relative to placebo, on clinical outcomes based on postrandomization…
Heart failure is one of the major health threats to women and men, with both sexes facing similarly high lifetime risks of developing heart failure…
This prespecified secondary analysis of a randomized clinical trial examines the efficacy and safety of finerenone in women and men with heart failure with mildly…
